ClinicalTrials.gg
Status unknownNCT04741165Updated Feb 5, 2021

Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

A Phase 2 interventional study of HX008 and Bevacizumab in Hepatocellular Carcinoma, sponsored by Taizhou Hanzhong biomedical co. LTD. Status unknown at 13 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-05.

Sponsored by Taizhou Hanzhong biomedical co. LTD · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,310 studies in Carcinoma, Hepatocellular with a site in China — 486 open to participants now, 558 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Planned enrollment
532nd of 1,034
72 · median 78
Started
2021
with 116 others
Phase 2
331 of 1,310
144 open now
Registered
573rd of 1,310
by date

Among the 1,310 studies in Carcinoma, Hepatocellular with a site in China, this one is the 532nd largest by planned enrollment of the 1,034 interventional ones that give a count, is one of 117 that started in 2021, is one of 331 in phase 2, and was the 573rd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

486 of the 1,310 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

481 more — sign in →

All 486 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,310 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody HX008 plus bevacizumab or lenvatinib in the first-line treatment of patients with unresectable hepatocellular carcinoma.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understood and signed an form.
  • Age ≥ 18 and ≤ 75 years old, male or female.
  • Has - or cytologically-confirmed diagnosis of unresectable hepatocellular carcinoma.
  • Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy or to locoregional therapy, and not amenable to a curative treatment approach.
  • class A and B (≤7 points).
  • Has not received any systematic treatment for HCC.
  • Has a performance status of 0 or 1 on the (ECOG) Performance Score.
  • ≥ 3 months.
  • Has at least one based on 1.1.
  • Has adequate organ function as defined in the protocol.
  • Female participants of should have a negative pregnancy within 7 days before the randomization. Male and female participants should agree to use an adequate method of during the experiment and 1 year after the last administration of the test drugs.

Exclusion criteria

Exclusion Criteria:

  • or cytologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc.
  • Diagnosed additional within 3 years prior to the first dose of trial, with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin,curatively resected in situ cervical or non-muscle invasive bladder cancers.
  • Has received locoregional therapy or surgery within 4 weeks prior to the first dose of trial treatment; received palliative radiotherapy or herbal medicine within 2 weeks prior to the first dose of trial treatment;
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  • >2000 IU/mL or 10\^4 copy/mL; >10\^3 copy/mL.
  • Has had esophageal or gastric variceal bleeding within the last 6 months.
  • Portal vein tumor thrombus (PVTT) involves both the main trunk and contralateral branch or upper mesenteric vein. Inferior vena cava tumor thrombus.
  • Other obvious hemorrhagic tendency or evidence on important coagulation disorder.
  • Serious cardiovascular and cerebrovascular diseases.
  • Inability to swallow tablets, malabsorption syndrome or any other condition that affects gastrointestinal absorption.
  • Serious, uncured wound, active ulcer or untreated bone fracture.
  • Uncontrolled pericardial effusion, uncontrolled pleural effusion or clinically obvious moderate peritoneal effusion at screening.
  • Has active disease that has required systemic treatment in past 2 years.
  • Has received a major surgery within 4 weeks prior to the first dose of tiral treatment.
  • Has received system treatment with (dose >10mg/day prednison or other therapeutic hormones) within 2 weeks prior to the first dose of trial treatment.
  • Has a history of non-infectious pneumonitis that required steroids or has current pneumonitis.
  • Has known active tuberculosis (Bacillus tuberculosis)
  • Has a history of testing positive for (HIV), or known acquired immunodeficiency syndrome (AIDS), or stem cell transplantation or organ transplantation.
  • Co-infection of HBV and HCV.
  • Any serious acute and chronic infection within 4 weeks prior to the first dose of trial treatment, or infection requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks prior to the first dose of trial treatment.
  • Has participated in other anticancer drug clinical trials within 4 weeks.
  • Has received a within 30 days prior to the first dose of trial treatment.
  • According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Experimental: HX008+Bevacizumab

    Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus bevacizumab 15 mg/kg, IV, Q3W.

    Drug: HX008 · Drug: Bevacizumab

  • Experimental
    Experimental: HX008+Lenvatinib

    Participants receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W) plus lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) orally once a day (QD).

    Drug: HX008 · Drug: Lenvatinib

Interventions

  • DrugHX008

    200 mg administered as IV infusion on Day 1 of each 21-day cycle.

  • 15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.

    Also known as: AVASTIN®

  • Administered orally once a day during each 21-day cycle

    Also known as: LENVIMA®

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who have a complete response (CR) or a partial response (PR), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.

    Time frame: Up to approximately 15 months

Secondary outcomes

  1. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who have a CR or a PR or a stable disease (SD), per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.

    Time frame: up to approximately 15 months

  2. Duration of Response (DOR)

    DOR was defined as the time from the first documented evidence of a response of CR or PR, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by investigators.

    Time frame: up to approximately 15 months

  3. Progression-free Survival (PFS)

    PFS was defined as the time from randomization to the first documented disease progression per RECIST 1.1 assessed by investigators or death due to any cause, whichever occurs first.

    Time frame: up to approximately 15 months

  4. Overall Survival (OS)

    OS was defined as the time from the date of beginning of HX008 administration until date of death from any cause.

    Time frame: up to approximately 20 months

  5. Time to Disease Progression (TTP)

    TTP is defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by investigators.

    Time frame: up to approximately 15 months

  6. Number of participants with adverse events (AEs)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment

    Time frame: up to approximately 20 months

07

Study locations

8 of 13 sites recruiting
  • The Fist Affiliated Hospital of USTC(Anhui Provincial hospital)
    Hefei, Anhui 230001, China
    Not yet recruiting
    • Lianxin Liu · Contact
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
    Recruiting
    • Jianqiang Cai · Contact
  • Beijing Yuhe Integrated Traditional Chinese and Western Medicine Rehabilitation Hospital
    Beijing, Beijing 100089, China
    Recruiting
    • Lianhai Zhang · Contact
  • Cancer Hospital Chinese Academy of Medical Sciences, shenzhen center
    Shenzhen, Guangdong 518116, China
    Not yet recruiting
    • Che Xu · Contact
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
    Recruiting
    • Yuxian Bai · Contact
  • Henan Cancer Hospital
    Zhengzhou, Henan 450004, China
    Not yet recruiting
    • Jufeng Wang · Contact
  • Hunan Provincial People's Hospital
    Changsha, Hunan 410000, China
    Recruiting
    • Xiaohai Mao · Contact
  • The First Affiliated University of Nanhua University
    Hengyang, Hunan 421000, China
    Recruiting
    • Wenxiang Dai · Contact
  • The Sixth People's Hospital of Shenyang
    Shenyang, Liaoning 110000, China
    Recruiting
    • Wei Wu · Contact
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
    Not yet recruiting
    • Jing Lv · Contact
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
    Not yet recruiting
    • Bo Li · Contact
  • Tianjin Cancer Hospital
    Tianjin, Tianjin 300000, China
    Recruiting
    • Tianqiang Song · Contact
  • The Central Hospital of Lishui City
    Lishui, Zhejiang 323000, China
    Recruiting
    • Jianfei Tu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Apr 2022, 15 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 15 months is below that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2021
First posted
Feb 5, 2021
StartActual
Jan 7, 2021
Primary completionEst.
Apr 30, 2022
CompletionEst.
Oct 30, 2022
Last update
Feb 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04741165
Lead sponsor
Taizhou Hanzhong biomedical co. LTD
Responsible party
Sponsor
First posted
Feb 5, 2021
Start date
Jan 7, 2021
Primary completion
Apr 30, 2022 (estimated)
Completion
Oct 30, 2022 (estimated)
Last update
Feb 5, 2021

Study contacts

Jianqiang Cai
Contact
caijianqiang188@sina.com
010-67781331

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pucotenlimab

Start the discussion